Endogenous retrovirus group W member 1, envelope glycoprotein (ERVW-1)

The **endogenous retrovirus group W member 1, envelope glycoprotein (ERVW-1, Syncytin-1)** is a membrane fusion protein derived from the *env* gene of the human endogenous retrovirus family HERV-W. It is highly expressed in the placenta, where it is essential for trophoblast cell fusion and formation of the multinucleated syncytiotrophoblast, a layer crucial for the exchange of nutrients and gases between mother and fetus and for maintaining maternal-fetal immune tolerance[1][2][3][4]. The protein consists of a surface unit (SU) and transmembrane unit (TM), forming a homotrimer, with SU binding cellular receptors (SLC1A4/ASCT1 and SLC1A5/ASCT2) to initiate membrane fusion. Syncytin-1 retains a unique immunosuppressive domain vital for pregnancy. Dysregulation of ERVW-1 is implicated in placental pathologies (pre-eclampsia), various cancers, neurodegenerative diseases (multiple sclerosis), and psychiatric disorders (schizophrenia, bipolar disorder), and is considered a disease biomarker in several contexts. Its structural and functional similarity with some viral proteins has led to safety concerns regarding therapeutic modulation, especially given its critical role during pregnancy[1][3][4].

Other names

Syncytin-1Surface proteinTransmembrane proteinERVW-1ERVWE1SUTMHERV-WHERV-W-ENVHERVWHERV-7qenvWEnv-WEnvelope polyprotein gPr73EnverinHERV-W envelope proteinHERV-W_7q21.2 provirus ancestral Env polyproteingp50gp24envelope proteinHERV-W Env glycoproteinENVENVWendogenous retroviral family Wenv(C7)member 1envelope glycoproteinhuman endogenous retrovirus W envC7-1 envelope protein

For experimental interventions (e.g., ferulic acid), antioxidant protection against syncytin-1-induced oxidative stress and neuroinflammation. In theory, inhibitors could impede membrane fusion or block receptor binding, but no clinical drugs have been validated for these pathways.